Background; This phase II study was conducted to evaluate the efficacy and toxicity of docetaxel in Japanese patients with advanced ovarian cancer.
Introduction
Docetaxel is a semisynthetic taxoid derived from the needles of the European yew, Taxus baccata, a plentiful and renewable source [1] . It is an analogue of paclitaxel, but has a more hydrophilic chemical structure and does not require cremophor as a solvent. Docetaxel demonstrates a unique mechanism for the induction of stable microtubule assembly and the promotion of tubulin polymerization, similar to that of paclitaxel [2] [3] [4] . Docetaxel has been proven to have potent cytotoxic activity in experimental in vivo and in vitro studies [5, 6] .
A phase I clinical study of docetaxel for solid tumors was conducted in Japan [7] . The recommended dose was determined to be 60 mg/m 2 as the result of that study. Subsequently, an early phase II study was carried out for advanced ovarian cancer in Japan [8] . Docetaxel 60 mg/m 2 was given as an over-one-hour infusion. In that study, only one (2.8%) of 36 patients achieved a partial response, and no complete remissions were seen. Therefore, we conducted a pilot dose escalation study of docetaxel (70, 75, 80 mg/m 2 ) for advanced ovarian cancer [9] . One complete remission and five partial remissions were obtained in twenty-five patients at the starting dose level of 70 mg/m 2 , and the overall response rate was 24%. The present phase II trial was designed to confirm the clinical efficacy and tolerability of docetaxel at 70 mg/m 2 in patients with advanced ovarian cancer. Serial measurements of serum CA125 levels have been shown to predict response to chemotherapy in patients with ovarian cancer who have elevated CA125 levels [10] . We assessed CA125 responses in this study and compared the CA125 response criteria with standard WHO response criteria.
Patients and methods

Patient selection
Patients were registered in the study from April 1995 to June 1997. To be eligible for this study, patients were histologically confirmed to have advanced epithelial ovarian cancer, and they met the following criteria: 1) one prior chemotherapy regimen including cisplatin and/or carboplatin: 2) the presence of at least one bidimensionally measurable target lesion; 3) four weeks from prior chemotherapy were required before study entry; 4) 15-74 years of age; 5) Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1; 6) WBC count >4000/ul and $ 10,000/ul, neutrophil count 3=2000/ul, platelet count 5=100,000/ul, hemoglobin 3=9.5 g/dl, serum bilirubin level $ 1.5 mg/dl, serum AST and ALT levels less than two times the upper limit of normal, serum albumin level J; 3.0 mg/dl, normal serum creatinine and blood urea nitrogen levels, PaO 2 >70 mmHg; and 7) estimated life expectancy 5= 3 months. Patients with active infection, severe heart disease, or a past history of hypersensitivity were excluded. Patients with peripheral neuropathy, pleural effusion that required drainage, active brain metastasis, or active concomitant malignancy were also excluded. All patients gave informed consent before participating in this study, which was approved by the institutional review boards at the participating institutions.
Patient evaluation
Before therapy, all patients had a complete history and physical examination, including a bimanual pelvic examination. Baseline laboratory studies included complete blood cell counts with differential (CBC), serum chemistries, CA125 determination, urinalysis, chest radiograph, and ECG. A CT scan and/or ultrasound of the abdomen and pelvis were performed before the initiation of treatment. Other scans were performed only if clinically indicated. Imaging tests for evaluation of target lesions were performed every treatment cycles and CBC were checked at least once weekly during the first two cycles. 
Treatment schedule
Docetaxel (Taxotere; RP 56976; Rhone-Poulenc Rorer, Collegeville, Pennsylvania) was supplied in 2 ml vials containing a drug solution prepared in polysorbate 80 at a concentration of 80 mg/ml. The starting dose of 70 mg/m 2 was diluted in 250 ml or 500 ml of 5% dextrose or 0.9% saline, and was given as a one-to two-hour infusion. The treatment was repeated every three weeks, provided the patient had sufficiently recovered from any toxicity. Treatment was to be performed for at least two cycles, unless progressive disease or unacceptable toxic effects were seen. Prophylactic regimens for nausea, vomiting, or hypersensitivity reactions were given only if these symptoms occurred.
No dose reduction was allowed. Although primary prophylactic colony-stimulating factors were not given, a secondary prophylactic administration of lenograstim (Neutrogin; Chugai Pharmaceuticals Inc., Tokyo, Japan) was allowed when febrile neutropenia and/or grade 4 leukocytopenia/neutropenia occurred in a prior cycle.
When hypersensitivity reactions occurred, the docetaxel administration was stopped and corticosteroids and anti-histamine were given intravenously. Chemotherapy was then resumed when all symptoms and signs subsided. Patients who experienced hypersensitivity reactions were pretreated with corticosteroids in subsequent courses
Response and toxicity evaluation
The tumor response was assessed according to the standard WHO criteria. Complete response (CR) was denned as the complete disappearance of all known disease for a minimum of four weeks, with no development of new disease. Partial response (PR) was defined as a 5= 50% reduction in the sum of products of measurable lesions for at least four weeks. Progressive disease (PD) was defined as a 5; 25% increase in the sum of the products of all indicator lesions, or the reappearance of any lesion that had disappeared, or the appearance of any new lesion. No change (NQ was defined by any situation that did not qualify as response or progression.
Patients with CA125 levels >50% of the upper limit of normal could be assessed according using mathematical logic and analyzed by a computer program, previously reported by Rustin et al. [10] . The CA125 response was defined according to the following criteria: 50% response: a response to a specific treatment has occurred if after two samples there has been a 50% decrease in the serum CA125 level, confirmed by a fourth sample, or 75% response: a response has occurred if there has been a serial decrease in the serum CA125 level over three samples of greater than 75%. For each criterion, the final sample must be taken at least 28 days after the previous sample. Responses (clinical complete, partial responses and CA125 responders) were strictly judged by an independent response evaluation committee (REC).
The Japan Society for Cancer Therapy (JSCT) criteria, which is similar to the WHO criteria, was used to evaluate toxicities.
Results
Patient characteristics
The patient characteristics are listed in Table 1 . Ninety patients with advanced ovarian cancer were entered from various institutions. Four were ruled ineligible: three with an inadequate evaluation of the measurable lesion, and one with treatment before registration. Of the 86 eligible patients, 26 were not assessable (NA) for response. One patient died during the first cycle because of multiorgan failure subsequent to disseminated intravascular coagulation without documentation of tumor progression, another was not administrated of any course of docetaxel because of sickness, and a third patient refused the treatment due to the drug adverse event of rash after the first cycle. Twenty-three patients were overdosed due to a misinterpretation; several hospital pharmacists or physicians misinterpreted the instructions for the preparation of the docetaxel infusion solution as described in the study protocol. The vials were overfilled, but instead of adding the entire contents of the solvent vial (7.33 ml) to the docetaxel vial, only the labeled theoretical volume (6 ml) was added. As the result of this misinterpretation, 23 patients may have received dosages up to 77 mg/m excluded from the assessments of the response and toxicity. Sixty-two patients were evaluable for toxicity.
The median age of all 60 assessable patients was 58 years and ranged from 33 to 73 years. All patients were pretreated with platinum-based chemotherapy but paclitaxel combination, and 36 (60%) patients were started on docetaxel within 6 months of their last platinum course. Median number of prior cycles of platinum-based chemotherapy was 6 (range 2-22).
Response
The 60 patients received a total of 248 courses of docetaxel and the median number of treatment course was 4 (range 1-10). Actually 244 (98%) courses were given without dose reduction. Three patients in four courses received a reduced dosage (50-60 mg/m 2 ) of docetaxel because of one with severe myelosuppression and two with hypersensitivity. The median interval of treatment was 24 days (range 19-72) and 83% of courses were given in the interval between 21 and 28 days. Table 2 describes the response assessment. The independent REC determined one complete remission and sixteen partial remissions. The objective response rate was 25% within 0-6 months of the platinum-free interval, 33% within 6-36 months, and 28.3% (17 of 60 patients) for both groups (95% confidence interval (95% CI): 16.6%-39.7%). Thirty-four patients were assessable for CA125 criteria, and 8 (23.5%) responded (95% CI: 10.8%-42.1%) ( gressed. The investigators identified 2 complete responses and 15 partial responses. Two clinical responded patients who had CR and PR were downgraded to PR and NC, respectively, and one patient with clinical NC but CA125 responder was upgraded to clinical PR by the judgment of REC. Therefore, overall response rate of REC was identical to that of investigators. Table 4 lists clinical responses according to histology and tumor site. Responses were seen in all histologic subtypes. Figure 1 shows the overall survival of 60 the assessable patients. The median follow-up time was 42.9 weeks, and the median survival was 53.3 weeks. The median time to response was 43 days (range 21-122 days). The median duration of response was 163 days (range 32-199 days).
Toxicity
Toxicity was evaluated for 62 assessable patients. The haematologic toxicity of docetaxel during all courses of treatment is summarized in Table 5 . Fifty-three (86%) patients experienced grade 3 or 4 neutropenia, and ten (16%) developed grade 3 or 4 anemia. Among the patients 15 (24%) patients developed febrile neutropenia (fever >38.0°C during grade 3 or 4 neutropenia). Thrombocytopenia occurred infrequently. Forty-seven (76%) patients in one hunderd sixty-eight (67%) courses were required administration of lenogratim. Table 6 summarizes the nonhaematologic toxicity during all courses of treatment. Alopecia was observed in 42 patients (68%) and was the most frequent non- Table 6 . Non-hematologic toxicity (worst of any course, n = 62) haematologic toxicity. Nausea/vomiting was induced in 31 patients (48%), but it was not severe. Sensory neuropathy was reported in 19 (31%) patients. We observed that 23 (37%) patients experienced a hypersensitivity reaction. One patient developed asthenia and severe dyspnea, which were transient; she soon recovered without treatment. Edema was seen in 10 (16%) patients. One patient developed a mild pleural effusion with peripheral edema.
Discussion
The efficacy of docetaxel at 100 mg/m 2 against ovarian cancer has been described in European and American phase II trials [11] [12] [13] [14] . Response rates of 26%-40% were demonstrated in each trial. Table 7 lists the phase II trials of docetaxel conducted worldwide. Early phase II trials with the dosage of 60 mg/m 2 in Japan for advanced ovarian cancer patients did not produce to have enough responders [8] . Therefore, a pilot study was conducted at the 70 mg/m 2 dose of docetaxel, achieving the response rate of 24% [9] . In the present trial, an equivalent response rate (28%) compared with European and American trials was achieved despite lower dosage of the drug. A Meta-analysis of these studies of the single-agent docetaxel against advanced ovarian cancer showed that the response rate at 100 mg/m 2 was 29.5% (93 among 315 patients, 95% CI: 24%-36%) [15] and that at 70 mg/m 2 was 25.3% (23 responders among 91 patients, 95% CI: 16%-34%). This difference is not significant (P = 0.351). In the present study, 23 patients were overdosed up to 77 mg/m 2 due to a misinterpretation. The response rate was 21.7% (1 of CR and 4 of PR) among the 23 patients, however haematologic toxicity was greater (100% ^ grade 3 neutropenia) and nonhaematologic toxicity occurred more frequently compared to the use of the 70 mg/m 2 dose (data not shown). In the phase II study at the 100 mg/m 2 dose, 41 (75%) of 55 patients actually needed a dose reduction from 100 to 75 mg/m 2 [12] . Almost all the patients (98%) were administrated without dose reduction in our trial; there- fore, the 70 mg/m 2 dose of docetaxel was considered to be safe and effective.
Patients who relapse less than six months after chemotherapy ends are deemed platinum-resistant, and treatment with an acceptable second-line agent is recommended [16, 17] . Our trial demonstrated that there was a response rate of 25% in the platinum-resistant patients (platinum-free interval 0-6 months) and 33% in the platinum-sensitive patients (platinum-free interval 6-36 months). The response rate was higher in the platinumsensitive patients than in platinum-resistant, but the difference was not significant (P = 0.56). These results indicate that docetaxel has modest activity for platinumresistant ovarian cancer patients.
Decreasing CA125 levels accurately indicate a tumor response. Several phase II trials of anti-tumor drugs showed a correlation between response rates according to CA125 criteria and standard criteria [18, 19] . In the present study, the CA125 response (8 of 34, 24%) was similar to the response using standard criteria (28%). A total of six patients were found to have responded using both methods of assessment; a further two patients showed a CA125 response but not a clinical response, compared with an additional three patients who showed a clinical response but not a CA125 response. One patient showed clinically progressive disease of peritoneal dissemination and liver metastasis as an assessable lesion after four cycles of docetaxel. but by the CA125 criteria she showed a response. The pretreatment CA125 level of this patient was 897 U/ml, and the CA125 level reached a nadir of 292 U/ml after three cycles. Then, CA125 level of the patient increased after four cycles of docetaxel. The discrepancy between this patients' clinical and CA125 responses is thought to be due to the inconsistency of the periods of assessment of these responses.
Although the hematologic toxicity of docetaxel in this trial was found to be similar to that in earlier trials at a higher dosage, the nonhaematologic toxicity was generally mild. Severe (grade 3-4) diarrhea and skin reaction, which occurred in 4%-10% of prior patients treated with the 100 mg/m 2 dose of docetaxel [15] , were not seen in our study. Hypersensitivity reactions are common toxicities, but were effectively prevented or minimized by premedication. In our trial, 37% of the patients developed hypersensitivity reactions and it was severe in only one patient. We did not design this trial with routine premedication; however, almost all of the hypersensitivity reactions were mild and could be minimized by treatment with antihistamines or corticosteroids. Severe fluid retention including pleural effusion or ascites was observed in 8%-12% of previous patients at the 100 mg/m 2 dose [15] . Only one of our patients developed pleural effusion. Recent studies indicated that premedication with corticosteroids could delay the onset of docetaxel-induced fluid retention [20] . However, we did not apply a routine use of corticosteroids. Fluid retention has been reported to be a cumulative toxicity for docetaxel and the median cumulative dose at the onset of fluid retention was 400 mg/m 2 [21] . That is the reason why the present patients showed a low incidence of fluid retention.
Conclusions
We conducted a phase II trial using 70 mg/m 2 of docetaxel for patients with advanced ovarian cancer. The overall response rate was 28% of the assessable patients, which is almost the same as the results of European and American trials. The main toxicity was neutropenia, and a low incidence of severe hypersensitivity reactions and/or edema was observed without any prophylactic premedication. We found the dose of 70 mg/m 2 of docetaxel to be less toxic and still effective in the treatment of both platinum-sensitive and platinumrefractory ovarian cancer patients.
